TAP Block With Liposomal Bupivacaine Versus Pre-incisional Wound Infiltration With Bupivacaine for Postoperative Pain
Information source: University of Tennessee
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Postoperative Pain
Intervention: Pre-incisional wound infiltration (Procedure); Laparoscope to place TAP block with liposomal bupivacaine (Procedure); Liposomal bupivacaine (Drug); Bupivacaine (Drug); Ketorolac (Drug)
Phase: Phase 1
Status: Not yet recruiting
Sponsored by: University of Tennessee Official(s) and/or principal investigator(s): Shanti I Mohling, MD, Principal Investigator, Affiliation: University of Tennessee
Overall contact: Shanti I Mohling, MD, Phone: 575-770-2841, Email: shantimohling@gmail.com
Summary
In this randomized, controlled, double-blinded trial we plan to evaluate post-operative pain
relief after laparoscopic-assisted Transversus Abdominis Plane (TAP) block using liposomal
bupivacaine plus bupivacaine versus pre-incisional would infiltration with bupivacaine in
patients undergoing Total laparoscopic or robotic assisted laparoscopic hysterectomy.
Clinical Details
Official title: Comparison of Laparoscopically Assisted Transversus Abdominis Plane Block Using Liposomal Bupivacaine With Pre-incisional Bupivacaine for Post-operative Pain Control in Patients Undergoing Laparoscopic or Robotic Hysterectomy
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention
Primary outcome: Visual Analog pain scores (VAS)
Secondary outcome: Narcotic pain medication usageNarcotic pain medication following surgery
Detailed description:
Patients undergoing laparoscopic or robotic assisted total hysterectomy at Erlanger Hospital
will be randomized into one of two groups to receive either laparoscopic assisted TAP block
with liposomal bupivacaine and bupivacaine (Group A) or pre-incisional bupivacaine (Group
B). The remaining aspects of the perioperative care, including the general anesthesia care
and postoperative care will be similar for all patients. Ideally, patients will be informed
and consented for the study in the preoperative clinic setting. They will be randomized in
the pre-anesthesia care unit.
Patients in Group A will receive laparoscopic-assisted bilateral TAP blocks using 10cc
liposomal bupivacaine, 10cc Bupivacaine 0. 25% and 10cc Normal Saline one each side.
Patients in Group B will receive a total of 20cc pre-incisional Bupivacaine divided between
each of the trocar sites. All patients will receive Ketorolac 30 mg, IV at the conclusion
of surgery. All patients will be offered either oral pain medications or patient controlled
anesthesia (PCA) opiate pain medication as indicated. Morphine equivalents will be
calculated.
Postoperative pain control will be assessed using Visual Analog Pain Score (VAS). This will
be done by recovery room personnel who will be blinded as to whether the patients received
TAP block or pre-incisional anesthetic. VAS will be assessed at rest at 1 hour and 2 hours
after arrival to PACU. Patients will be assessed with Overall Benefit of Anesthesia Score
(OBAS) questionnaires at postoperative days 1, 2 and 7. OBAS questionnaires will be done by
personnel blinded to anesthesia technique. Patients will also be blinded as to which group
they were in. Total morphine equivalents of intraoperative and postoperative pain
medications will be calculated through postoperative day 7.
Eligibility
Minimum age: 18 Years.
Maximum age: 80 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- ASA physical status 1-3,
- Scheduled for laparoscopic or robotic assisted laparoscopic hysterectomy,
- Able to participate personally or by legal representation in informed consent
Exclusion Criteria:
- History of relevant allergy to the study drugs (Bupivacaine),
- Chronic opioid use or drug abuse history,
- Inability to understand the study protocol,
- Refusal to provide written consent,
- Soft tissue infection of the abdominal wall and skin
Locations and Contacts
Shanti I Mohling, MD, Phone: 575-770-2841, Email: shantimohling@gmail.com Additional Information
Starting date: March 2015
Last updated: March 26, 2015
|